Cargando…
P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
Autores principales: | Garcia-Manero, Guillermo, Bachishvili, Kimo, A. Griffiths, Elizabeth, M. Zeidan, Amer, Traer, Elie, Saini, Lalit, Amin, Harshad, Mohan, Sanjay, Lübbert, Michael, Maness-Harris, Lori, M Foran, James, Selleslag, Dominik, Xicoy Cirici, Blanca, Aaron Pollyea, Daniel, Sallman, David, Al-Kali, Aref, Berdeja, Jesus, Kathrin Al-Ali, Haifa, Y Zhu, Nancy, Font Lopez, Patricia, Sanz Santillana, Guillermo, Santini, Valeria, A. Yimer, Habte, D Cripe, Larry, Priego, Victor, Odenike, Olatoyosi, Heyrman, Bert, Valcarcel, David, Vachhani, Pankit, Sano, Yuri, Mirakhur, Beloo, Oganesian, Aram, Keer, Harold, Yacoub, Abdulraheem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428680/ http://dx.doi.org/10.1097/01.HS9.0000969780.55126.5b |
Ejemplares similares
-
P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
por: Robert Savona, Michael, et al.
Publicado: (2023) -
Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
por: Savona, Michael R., et al.
Publicado: (2021) -
PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023) -
Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020) -
Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2021)